The Sahlgrenska University Hospital is a hospital network associated with the Sahlgrenska Academy at the University of Gothenburg in Gothenburg, Sweden. With 17,000 employees the hospital is the largest hospital in Sweden by a considerable margin, and the second largest hospital in Europe.

There are 2,000 beds in Sahlgrenska University Hospital Department of Hematology and Coagulation.

During the past decade, Sahlgrenska University Hospital Department of Hematology and Coagulation conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 1 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sahlgrenska University Hospital Department of Hematology and Coagulation" #1 collaborator was "NordForsk" with 2 trials as a collaborator, "The Swedish Childhood Cancer Foundation" with 2 trials as a collaborator, "Aamu Pediatric Cancer Foundation" with 1 trials as a collaborator, "Acreditar - Associação de Pais e Amigos das Crianças com Cancro" with 1 trials as a collaborator and "Amgen" with 1 trials as a collaborator. Other collaborators include 14 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Sahlgrenska University Hospital Department of Hematology and Coagulation" are "Leukemia, Acute Lymphoblastic" (2 trials), "Multiple Myeloma" (2 trials), "DLBCL" (1 trials), "Diffuse Large B Cell Lymphoma" (1 trials) and "MCL" (1 trials). Many other conditions were trialed in "Sahlgrenska University Hospital Department of Hematology and Coagulation" in a lesser frequency.

Most popular intervention types in "Sahlgrenska University Hospital Department of Hematology and Coagulation" are "Drug" (5 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "6-tioguanine+Standard Maintenance Therapy" (1 trials), "Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma" (1 trials), "Blinatumomab" (1 trials), "Bortezomib" (1 trials) and "CC-5013 plus dexamethasone" (1 trials). Other intervention names were less common.

The vast majority of trials in "Sahlgrenska University Hospital Department of Hematology and Coagulation" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Sahlgrenska University Hospital Department of Hematology and Coagulation". undefined are not yet recruiting, 5 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Sahlgrenska University Hospital Department of Hematology and Coagulation, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Sahlgrenska University Hospital Department of Hematology and Coagulation, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".